Compare ISTR & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ISTR | ACHV |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 394.5M | 172.0M |
| IPO Year | 2014 | 2018 |
| Metric | ISTR | ACHV |
|---|---|---|
| Price | $28.00 | $4.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $31.50 | $14.67 |
| AVG Volume (30 Days) | 146.8K | ★ 1.2M |
| Earning Date | 04-20-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.59% | N/A |
| EPS Growth | ★ 4.41 | N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $66.56 | N/A |
| Revenue Next Year | $5.18 | N/A |
| P/E Ratio | $35.87 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.89 | $2.00 |
| 52 Week High | $30.49 | $6.15 |
| Indicator | ISTR | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 50.31 | 50.61 |
| Support Level | $26.37 | $4.65 |
| Resistance Level | $28.84 | $4.78 |
| Average True Range (ATR) | 0.53 | 0.40 |
| MACD | -0.04 | 0.03 |
| Stochastic Oscillator | 48.76 | 31.40 |
Investar Holding Corp is a U.S.-based financial holding company. Through its subsidiaries, it offers a variety of commercial and retail lending products throughout its market areas, including business loans to small to medium-sized businesses, as well as loans to individuals. It has business operations spread across the United States and serves its customers through several service branches. The bank also offers cashier's checks, direct deposit of payroll and Social Security checks, night depository, bank-by-mail, automated teller machines with deposit automation, and debit cards.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.